DataMEDS AI, Inc. (MEDS)
| Market Cap | 8.48M -84.5% |
| Revenue (ttm) | 8.02M -78.2% |
| Net Income | -88.28M |
| EPS | -43.73 |
| Shares Out | 3.06M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 192,658 |
| Open | 2.710 |
| Previous Close | 2.850 |
| Day's Range | 2.650 - 2.800 |
| 52-Week Range | 0.823 - 73.000 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 19, 2026 |
About MEDS
DataMEDS AI, Inc. operates as a health IT company in the United States. The company focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent, and telemedicine business units to deliver an enhanced healthcare experience for consumers. It offers tools, such as the EinsteinRx, a pharmacy dispensing AI platform; the PharmacyChain, a smart contracts platform; Patient Rx Adherence Tool; and HubRx AI. It also operates as a pharmacy distributor; and provides clinical concierge services. DataMEDS AI, Inc., through its subsidi... [Read more]
Financial Performance
In 2025, DataMEDS AI's revenue was $23.34 million, an increase of 28.73% compared to the previous year's $18.13 million. Losses were -$101.27 million, 1377.1% more than in 2024.
Financial StatementsNews
DataMEDS Si Licenses U.S. Rights To Reboot Health AI's Direct-To-Consumer GLP-1 Weight Management Platform
Platform to be integrated into Health Lives Here app as a subscription offering TAMPA, FL / ACCESS Newswire / October 14, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMED...
DataMEDS SI Provides Business Update On CLIA Lab Helomics And Its Super Intelligence Predictive Oncology Division
Leading Health IT Company has Implemented Cost Control Measures and Refocused Remaining Workforce Towards ChemoFx® Commercialization with Hospital Systems, HMOs, GPOs and Cancer Centers TAMPA, FL / AC...
DataMEDS SI Announces Helomics Receives Medicaid Coverage Policy For Chemofx(R) Assay In Gynecologic Cancers
Humana adds ChemoFx® to its Medicaid Pharmacogenomics Testing coverage policy TAMPA, FL / ACCESS Newswire / October 12, 2026 / DataMeds AI, Inc . (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS...
Datameds AI Files DBAs Datameds SI And Corexa Health SI And Reminds Shareholders Of Record As Of August 7, 2026 Of Dream Bowl Meme Coin I Payment
Healthcare IT Company and its Subsidiary Undertake Action Following US Government's Updated Nomenclature TAMPA, FL / ACCESS Newswire / October 5, 2026 / DataMeds AI, Inc . (NASDAQ:MEDS) ("DataMeds AI,...
DataMeds AI's Corexa Pharmacy Surpasses $1 Million In Monthly Revenue
September 2026 revenue up more than 66 percent from July 2026 with expansion of retail customer base and Tollo Health pharmaceutical-adjunct product launches TAMPA, FL / ACCESS Newswire / October 1, 2...
DataMeds AI and Tollo Health Announce Launch of 'Health Lives Here' Mobile Application
Healthcare IT Company and Nutritional Products Maker to Work with NFL Alumni Health to Drive Awareness of GLP-1 Telehealth and Pharmacy Services TAMPA, FL / ACCESS Newswire / September 28, 2026 / Data...
DataMEDS AI To Present At 2026 National Telehealth and Virtual Care Summit
Interim Co-CEO to Discuss Growing Patient Desire to Own Health Data TAMPA, FL / ACCESS Newswire / September 25, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS," or the "Company"), a ...
DataMEDS AI Unveils New Corporate Website
Updated Website Aligns with Pending Marketing Initiatives Following Recent Acquisition of Helomics CLIA-certified Laboratory and Litigation Settlement TAMPA, FL / ACCESS Newswire / September 21, 2026 ...
DataMeds AI Litigation Settlement Extinguishes ~$19 million In Liabilities and Retires 364,099 Common Sharessked
TAMPA, FL / ACCESS Newswire / September 18, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastruct...
DataMeds AI Inc trading resumes
09:41 EDT DataMeds AI (MEDS) Inc trading resumes
DataMeds AI Inc trading halted, volatility trading pause
09:31 EDT DataMeds AI (MEDS) Inc trading halted, volatility trading pause
This AI stock experienced a 5x rally on Wednesday
DataMeds AI (MEDS) shares ripped higher on Wednesday morning as the company completed its acquisition of Helomics AI cancer diagnostics laboratory and precision oncology contract research organization...
DataMEDS AI acquires Helomics subsidiary from Axe Compute for $1.5M
DataMEDS AI (MEDS) announced that it completed the acquisition of artificial intelligence cancer diagnostics laboratory business Helomics from Axe Compute (AGPU). Under the agreement, DataMEDS acquire...
DataMEDS, AI. Acquires Helomics AI Cancer Diagnostics Lab and Precision Oncology CRO Businesses from Axe Compute
Acquisition Provides Operational Capital to Drive Health Lives Here Campaign and Expand Services into Cancer Management PITTSBURGH, PA / ACCESS Newswire / September 15, 2026 / DataMEDS AI, Inc. (NASDA...
Why Is DataMeds AI Stock (MEDS) Up Nearly 200% Today?
DataMeds AI stock was up almost 200% on Tuesday after the company announced a deal with Axe Compute.
Axe Compute sells Helomics to DataMEDS AI, terms undisclosed
Axe Compute (AGPU) announced the sale of its legacy artificial intelligence cancer diagnostics laboratory business Helomics to DataMEDS AI (MEDS). Under the agreement, Axe Compute sold its wholly-owne...
Datameds, AI., and Tollo Health Partner with the NFL Alumni Association for Health Lives Here National Campaign Rollout
Leading Healthcare IT Company and Former NFL Players Will Work Together to Provide Rural Communities Access to Telehealth and Pharmacy-based Services Through Health Lives Here Mobile App TAMPA, FL / A...
DataMeds AI and Tollo Health Announce Fall 2026 Cold & Flu #Back2School50% Marketing Campaign for Viral Infections Medical Food Galectovid(TM)
50% off available online at www.TolloHealth.Shop and www.CorexaRx.com Soon to become available at Health Lives Here™ pharmacies and on Amazon.com TAMPA, FL / ACCESS Newswire / August 27, 2026 / Dat...
DataMEDS AI reports Q2 EPS ($7.13) vs. ($5.40) last year
Reports Q2 revenue $1.78M vs. $7,8M last year. “Having been in leadership now for just under three months, I am excited with the significant progress we are making towards the…
DataMeds AI Reports Second Quarter 2026 Financials and Provides Business Update
Revenues grew 14% reaching $1.779M in Q2/26, beating management projections Corporate name change from Wellgistics Health, Inc. to DataMeds AI, Inc. in July 2026, which led to stock symbol change from...
DataMEDS AI provides update on Corexa Pharmacy
DataMeds AI (MEDS) provided an update on the Company’s pharmaceuticals-focused subsidiary Corexa Health’s pharmacy division Corexa Pharmacy. The company said, “Corexa Pharmacy recently achieved severa...
DataMEDS AI Announces Its Board of Directors Approved September 9, 2026 as the Payment Date of the Previously Announced Distribution of Dream Bowl Meme Coin I Tokens to Record Holders of Common Stock and other Eligible Equity Securities as of the Record Date of August 7, 2026
TAMPA, FL / ACCESS Newswire / August 14, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMEDS AI," "DataMEDS," or the "Company"), an integrated healthcare company leveraging its Health IT infrastructure ...
DataMeds AI Provides Update on Corexa Health's Pharmacy Division
GLP-1 agonist drugs now available Integration of online store CorexaRx.com into Health Lives Here app now complete Medical foods Forzet™ & Galectovid™, and dietary supplement Tollovid® now available R...
DataMEDS AI renames pharmacy subsidiaries under Corexa Health division
DataMeds AI (MEDS) announced that it has completed the name changes of its pharmacy and pharmacy hub subsidiaries to Corexa Pharmacy and Corexa Tech & Hub, respectively. Corexa Pharmacy and…
DataMeds AI Renames Pharmacy Subsidiaries Corexa Pharmacy and Corexa Tech & Hub Under New Corexa Health Division
TAMPA, FL / ACCESS Newswire / August 10, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS," or the "Company"), a Health IT company leveraging its artificial intelligence platform Einst...